Cna Financial Corp I Teos Therapeutics, Inc. Transaction History

Cna Financial Corp

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 09, 2022	SELL	$16.57 - $35.1 $166,611 - $352,930	-10,055 Closed	0 $0
Q1 2022 May 10, 2022	SELL	$31.92 - $47.45 $80,438 - $119,574	-2,520 Reduced 20.04%	10,055 $324,000
Q4 2021 Feb 11, 2022	SELL	$26.23 - $47.86 $38,033 - $69,397	-1,450 Reduced 10.34%	12,575 $585,000
Q2 2021 Aug 12, 2021	BUY	$17.9 - $36.1 $18,795 - $37,905	1,050 Added 8.09%	14,025 $360,000
Q1 2021 May 14, 2021	BUY	$30.86 - $44.2 $9,875 - $14,144	320 Added 2.53%	12,975 $443,000
Q4 2020 Feb 12, 2021	BUY	$21.59 - $33.95 $80,098 - $125,954	3,710 Added 41.48%	12,655 $428,000
Q3 2020 Nov 12, 2020	BUY	$17.57 - $32.92 $157,163 - $294,469	8,945 New	8,945 $221,000

159

39M

1.95M

351K

Ticker ITOS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,575,300
Market Cap $259M
Description
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...

Get notified when there are updates to the investment portfolio of Cna Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Cna Financial Corp with notifications on news.